ERAS · NASDAQ · Biotechnology

Erasca (ERAS)

Develops pan-RAS and pan-KRAS therapies for RAS/MAPK-driven solid tumors.

$15.55
After hours+0.01 (+0.03%)
At close$15.55(+3.36%)